



Robert Freedman, Chairman and CEO

Dear friends of Hurel,

Please join me in welcoming Cyprotex as the latest major CRO to add the HμREL[®] microliver platform to its portfolio of client services.

As their [data sheet](#) indicates, Cyprotex have independently validated the HμRELhumanpool[™] multi-donor co-culture model for clearance studies, extending their incubations over 72 hours and demonstrating replicable prediction of clearance rates within two-fold of in vivo for twelve out of thirteen well-studied compounds, eight of which are classified as low-clearance (intrinsic clearance <3.85μL/min/10⁶ cells). To all who work in our field, the significance of these data will be immediately apparent.

The long incubation periods also enabled Cyprotex to identify metabolites for low-clearance compounds that could not be detected in a short-term suspension model.

I would like to thank Phil Butler, Jo Wilcock, and their teammates at Cyprotex for their interesting research and collaboration.

Respectfully,

Robert Freedman



hurelcorp.com